← All trials
NCT04895020
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- May 28, 2021
- Primary completion
- Dec 31, 2021
- Completion date
- May 31, 2026
- First posted
- May 20, 2021
- Last posted
- Jun 21, 2021
- Enrollment
- 1200
- Arms / groups
- 1 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Shanghai Bovax Biotechnology Co., Ltd.Lead sponsor
- Government of ChinaStudy director
- Shanghai Bovax Biotechnology Co., Ltd.Collaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.